Cambridge, United States
Totient - Part of Absci, founded in 2017, is a pioneering AI-driven biotechnology company headquartered in the United States. Their core focus is leveraging Artificial Intelligence for Drug Discovery, which involves harnessing tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and subsequently develop high-affinity antibody therapeutics.
By reconstructing antibodies from patient tissues affected by autoimmune conditions, infections, and cancer, Totient has notably addressed both known and novel extracellular oncology targets. Among these targets are GAGE1, GAGE2A, ANXA1, and others.
The company's strategic approach and innovative platform have attracted significant attention, culminating in its acquisition by ABCI Investment Management on 01 June 2021. This acquisition underscores the potential and growth prospects of Totient’s pioneering technology in redefining drug discovery within the biopharmaceutical landscape.
